For two reasons:
1- We own 100% of 534 and only have a % of sales of Rida.
2- 534 is at the stage that the all important pivotal trial is starting and much info on the design, prospects of success and market must be divulged to the shareholders, while Rida is at the stage that, with one exception, nothing new will happen for about three months (till the final results will be reported on). In addition, it may very well be possible that Merck will take the lead in reporting Rida progress (which might be part of the new agreement between Merck and Ariad). The one exception alluded to, is that by the end of this month, at a International Scientific Meeting, results of the Rida Endometrial Phase 11 trial will be reported on.
JMHO, Barry
